Detection of amyloid beta protein in the urine of Alzheimer's disease patients and healthy individuals.

Abstract

To seek for a new valid biomarker using non-invasive specimens for the diagnosis of Alzheimer's disease (AD) and mild cognitive impairment (MCI), we carried out the detection of amyloid beta (Abeta) protein in urine. Ten-millilitre urine samples were first sedimented with trichloroacetic acid, and the pellets were resuspended for further analysis by Western blotting with anti-Abeta antibody. The detection sensitivity of the method was 40pg/ml. Rates of subjects positive for monomeric Abeta according to their clinical dementia rating (CDR) were 11.1% for CDR 0, 62.5% for CDR 0.5, 83.3% for CDR 1, 54.5% for CDR 2 and 0% for CDR 3. A single Abeta band relative to the CDR score reflects an alteration in the production, solubility and clearance of Abeta in the brain. Thus, the method could be used as both a diagnostic and monitoring tool in assessing AD and MCI patients during disease-modifying therapies.

• Authors: Manabu Takata, Manabu Nakashima, Taro Takehara, Hideyo Baba, Kazuyuki Machida, Yoshiharu Akitake, Kazuhiko Ono, Masato Hosokawa, Mitsuo Takahashi
• Journal: Neuroscience letters (Neurosci Lett) Vol. 435 Issue 2 Pg. 126-30 (Apr 18 2008) ISSN: 0304-3940 [Print] Ireland
• PMID: 18343031 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Amyloid beta-Peptides
• Peptide Fragments
• amyloid beta-protein (1-42)

Topics

• Aged
• Aged, 80 and over
• Alzheimer Disease (urine)
• Amyloid beta-Peptides (urine)
• Cognition Disorders (urine)
• Female
• Humans
• Male
• Middle Aged
• Peptide Fragments (urine)
• Severity of Illness Index